Authors
Latest:
Medicine for the Planet: Building a Sustainable Legacy in Pharma Supply ChainsNew innovations that are contributing to industry environmental efforts.
Latest:
How Healthcare Economics Outcomes Evidence Can Pave the Way for Digital TherapeuticsIn the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.
Latest:
Exclusivity Creates Challenges in Price, Access for Long-used MedicationsFDA’s Unapproved Drug Initiative (UDI) is a well-intentioned program in its encouragement of formal FDA review for unapproved legacy medications. But it has inadvertently created financial challenges and access issues, write Steven Lucio and Jenna Stern
Latest:
Health policies high on specialty radar in 2021The key trends and considerations for specialty providers navigating a changing policy landscape
Latest:
Revolutionizing Rare Disease Treatment: Embracing the Patient-Centric Transformation in Pharmaceutical Customer EngagementNavigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.
Latest:
Critical Year Ahead for the 340B Drug Pricing ProgramThe courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.
Latest:
Navigating the Biosimilars MarketplaceHow to provide effective brand engagement in this rocky yet emerging landscape.
Latest:
Future of Personalized Medicine Hinges on Pharma Executives Revolutionizing Business ModelsThe era of big pharma as product-first companies must end, as services become the larger priority.
Latest:
Applying AI Case Studies in PharmaHow artificial intelligence and real-world data has not just helped predict patient behavior, but has also been successful at the point-of-care for life sciences companies.
Latest:
Medical Affairs Role in Shaping StrategyWhat the Changing Healthcare Landscape Demands of Future MA Professionals?
Latest:
Unpacking the High Cost of GLP-1 DrugsHow can industry stakeholders ensure the quality and supply chain security of existing product?
Latest:
Illinois Governor Signs Legislation Targeting PBM RetaliationIllinois Governor JB Pritzker signed into a law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.
Latest:
Leading in Challenging TimesIt has been said that one should never miss an opportunity to make the most of a crisis. The steady stream of headlines announcing staff cuts, delays in drug approvals and a narrowing of R&D focus for pharmaceutical and biotech companies indicate there will be no shortage of opportunities in 2009.
Latest:
Coordinating payer contracts and direct-to-patient discountingAlthough controversial, patient-focused discounts can play a valuable role in managed-markets programs
Latest:
Follow-on Biologics: A Patent Litigation PerspectiveIn whatever form biosimilar legislation might take, patent holders will need to review their patent portfolios carefully
Latest:
Sales Force Automation's Latest Kick: Mobile and Touch-Display ApplicationsA pronounced fascination with Apple Computer's iPad is focusing sales-IT efforts on mobility and data access; meanwile, online e-detailing offerings win more acceptance
Latest:
The path to digital transformation runs through dataKey priorities: cleansed data and consolidated databases
Latest:
Risky Business: What Life Sciences Need to Know About the US Foreign Corrupt Practices Act Before an AcquisitionNearly 30% of acquiring companies do not evaluate FCPA risks prior to an acquisition
Latest:
Safety Issues Dominate Pain MarketWhile researchers study new pain-killing pathways, the pharma industry tries drug combinations and alternative-delivery mechanisms By Angelo DePalma, PhD
Latest:
Medical marijuana looks for a place in conventional drug distributionIt's still early days in making medical marijuana--and cannabis-based pharmaceuticals--part of normal dispensing
Latest:
The Impending AMP Rule, still waiting three years laterSome state-level changes give an indication of what to prepare for
Latest:
Getting ready for Sunshine Act public dataHow to prepare for reporting and utilizing published data for business and compliance purposes
Latest:
Welcome to the new era of outsourced sales and clinical field forcesPushing your frontline into a new frontier
Latest:
For better patient data in pharma, think CUPIDA Common Universal Patient de-IDentifier could greatly enhance the value of industry data assets
Latest:
Vaccine growth spurs device, contract-services marketsA double-digit growth rate through 2024 means boom times for drug-delivery devices and for contract manufacturing services
